Global Medical REIT (GMRE) Financials

$7.80 +0.11 (+1.36%)

Closing price 05/2/2025 03:59 PM Eastern

Extended Trading

$7.80 -0.01 (-0.13%)

As of 05/2/2025 05:30 PM Eastern

Annual Income Statements for Global Medical REIT

This table shows Global Medical REIT's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	13	15	0.81
Consolidated Net Income / (Loss)	20	22	6.69
Net Income / (Loss) Continuing Operations	13	7.04	4.20
Total Pre-Tax Income	13	7.04	4.20
Total Revenue	112	110	110
Net Interest Income / (Expense)	-25	-31	-29
Total Interest Income	0.00	0.00	0.00
Total Interest Expense	25	31	29
Long-Term Debt Interest Expense	25	31	29
Total Non-Interest Income	137	141	139
Other Service Charges	0.12	0.12	0.37
Other Non-Interest Income	137	141	138
Total Non-Interest Expense	99	103	106
Other Operating Expenses	42	45	50
Depreciation Expense	40	41	40
Amortization Expense	17	17	15
Restructuring Charge	0.35	0.04	0.16
Other Gains / (Losses), net	0.00	-0.87	-1.72
Net Income / (Loss) Discontinued Operations	6.75	16	4.21
Preferred Stock Dividends Declared	5.82	5.82	5.82
Net Income / (Loss) Attributable to Noncontrolling Interest	0.85	1.12	0.06
Basic Earnings per Share	$0.20	$0.23	$0.01
Weighted Average Basic Shares Outstanding	65.46M	65.55M	65.94M
Diluted Earnings per Share	$0.20	$0.23	$0.01
Weighted Average Diluted Shares Outstanding	65.46M	65.55M	65.94M
Weighted Average Basic & Diluted Shares Outstanding	65.53M	65.57M	66.87M
Cash Dividends to Common per Share	$0.84	$0.84	$0.84

This table shows Global Medical REIT's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	8.06	0.37	0.67	12	3.14	-0.84	0.79	-3.15	1.79	1.37
Consolidated Net Income / (Loss)	10	1.85	2.17	14	4.83	0.55	2.31	-1.95	3.39	2.94
Net Income / (Loss) Continuing Operations	3.28	1.85	1.69	1.39	2.54	1.42	2.31	1.43	1.57	-1.11
Total Pre-Tax Income	3.28	1.85	1.69	1.39	2.54	1.42	2.31	1.43	1.57	-1.11
Total Revenue	28	28	28	28	28	26	28	27	27	28
Net Interest Income / (Expense)	-6.96	-8.07	-8.27	-8.47	-7.17	-6.98	-6.89	-6.99	-7.24	-7.57
Total Interest Expense	6.96	8.07	8.27	8.47	7.17	6.98	6.89	6.99	7.24	7.57
Long-Term Debt Interest Expense	6.96	8.07	8.27	8.47	7.17	6.98	6.89	6.99	7.24	7.57
Total Non-Interest Income	35	36	36	36	36	33	35	34	34	35
Other Service Charges	0.06	0.02	0.03	0.03	0.02	0.03	0.05	0.03	0.09	0.21
Other Non-Interest Income	35	36	36	36	35	33	35	34	34	35
Total Non-Interest Expense	25	26	26	26	26	25	26	26	25	29
Other Operating Expenses	11	11	11	12	12	10	12	12	12	15
Depreciation Expense	10	11	10	10	10	10	10	10	9.99	10
Amortization Expense	4.29	4.51	4.40	4.34	4.10	4.04	3.97	3.87	3.65	3.45
Restructuring Charge	0.11	0.11	0.04	0.00	0.00	-	0.00	0.00	0.00	0.16
Net Income / (Loss) Discontinued Operations	6.75	-	0.49	13	2.29	-	0.00	-3.38	1.82	5.77
Preferred Stock Dividends Declared	1.46	1.46	1.46	1.46	1.46	1.46	1.46	1.46	1.46	1.46
Net Income / (Loss) Attributable to Noncontrolling Interest	0.52	0.02	0.05	0.90	0.24	-0.07	0.07	-0.26	0.15	0.11
Basic Earnings per Share	$0.12	$0.01	$0.01	$0.18	$0.05	($0.01)	$0.01	($0.05)	$0.03	$0.02
Weighted Average Basic Shares Outstanding	65.52M	65.46M	65.53M	65.54M	65.57M	65.55M	65.57M	65.59M	65.74M	65.94M
Diluted Earnings per Share	$0.12	$0.01	$0.01	$0.18	$0.05	($0.01)	$0.01	($0.05)	$0.03	$0.02
Weighted Average Diluted Shares Outstanding	65.52M	65.46M	65.53M	65.54M	65.57M	65.55M	65.57M	65.59M	65.74M	65.94M
Weighted Average Basic & Diluted Shares Outstanding	65.52M	65.53M	65.53M	65.56M	65.56M	65.57M	65.59M	65.59M	66.80M	66.87M

This table details how cash moves in and out of Global Medical REIT's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	1.70	-7.73	2.22
Net Cash From Operating Activities	77	68	70
Net Cash From Continuing Operating Activities	77	68	70
Net Income / (Loss) Continuing Operations	20	22	6.69
Consolidated Net Income / (Loss)	20	22	6.69
Depreciation Expense	40	41	40
Amortization Expense	20	20	18
Non-Cash Adjustments to Reconcile Net Income	-1.58	-8.99	2.99
Changes in Operating Assets and Liabilities, net	-1.74	-5.69	2.04
Net Cash From Investing Activities	-137	68	-46
Net Cash From Continuing Investing Activities	-137	68	-46
Purchase of Investment Securities	-156	-11	-103
Sale and/or Maturity of Investments	18	79	57
Other Investing Activities, net	1.00	0.00	0.00
Net Cash From Financing Activities	62	-144	-22
Net Cash From Continuing Financing Activities	62	-144	-22
Net Change in Deposits	-1.97	7.16	0.25
Issuance of Debt	139	83	144
Issuance of Common Equity	9.90	0.00	11
Repayment of Debt	-20	-169	-111
Payment of Dividends	-64	-65	-66
Cash Interest Paid	22	30	27

This table details how cash moves in and out of Global Medical REIT's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	-0.61	0.86	-0.47	-4.20	-2.17	-0.89	1.08	0.01	-0.03	1.15
Net Cash From Operating Activities	18	18	16	18	17	18	14	19	16	21
Net Cash From Continuing Operating Activities	18	18	16	18	17	18	14	19	16	21
Net Income / (Loss) Continuing Operations	10	1.85	2.17	14	4.83	0.55	2.31	-1.95	3.39	2.94
Consolidated Net Income / (Loss)	10	1.85	2.17	14	4.83	0.55	2.31	-1.95	3.39	2.94
Depreciation Expense	10	11	10	10	10	10	10	10	9.99	10
Amortization Expense	5.06	5.38	5.27	5.19	4.87	4.79	4.68	4.58	4.39	4.26
Non-Cash Adjustments to Reconcile Net Income	-5.54	1.15	0.22	-11	-0.86	3.11	1.44	5.61	-0.61	-3.44
Changes in Operating Assets and Liabilities, net	-1.36	-0.65	-2.38	-0.50	-2.27	-0.54	-4.25	0.57	-0.86	6.57
Net Cash From Investing Activities	-33	-1.41	3.09	62	5.66	-3.11	-2.72	1.79	-25	-20
Net Cash From Continuing Investing Activities	-33	-1.41	3.09	62	5.66	-3.11	-2.72	1.79	-25	-20
Purchase of Investment Securities	-53	-1.89	-0.81	-2.53	-3.86	-4.11	-2.55	-5.21	-36	-59
Sale and/or Maturity of Investments	18	0.17	4.05	64	9.53	1.00	-0.17	7.49	12	38
Other Investing Activities, net	1.49	0.30	-0.15	0.15	-	-	0.00	-0.50	-0.75	1.25
Net Cash From Financing Activities	15	-16	-19	-84	-25	-16	-10	-21	9.16	0.15
Net Cash From Continuing Financing Activities	15	-16	-19	-84	-25	-16	-10	-21	9.16	0.15
Net Change in Deposits	-0.44	-0.57	-0.64	-0.26	-0.14	8.20	-0.06	0.31	-0.02	0.02
Issuance of Debt	35	12	13	12	14	45	14	25	44	61
Repayment of Debt	-3.53	-11	-15	-80	-22	-53	-8.03	-29	-30	-44
Payment of Dividends	-16	-16	-16	-16	-16	-16	-16	-16	-16	-17
Cash Interest Paid	6.21	6.37	8.14	8.15	7.00	6.86	6.41	6.18	6.94	7.05

This table presents Global Medical REIT's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Total Assets	1,393	1,268	1,256
Cash and Due from Banks	4.02	1.28	6.82
Restricted Cash	10	5.45	2.13
Interest Bearing Deposits at Other Banks	7.83	0.67	0.71
Trading Account Securities	35	25	19
Loans and Leases, Net of Allowance	0.00	0.00	0.00
Premises and Equipment, Net	1,072	974	953
Deferred Acquisition Cost	30	27	28
Goodwill	5.90	5.90	5.90
Intangible Assets	148	139	139
Other Assets	81	89	102
Total Liabilities & Shareholders' Equity	1,393	1,268	1,256
Total Liabilities	744	662	701
Non-Interest Bearing Deposits	5.46	3.69	3.32
Short-Term Debt	636	585	632
Other Short-Term Payables	30	29	33
Long-Term Debt	58	26	14
Other Long-Term Liabilities	15	18	18
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	649	606	556
Total Preferred & Common Equity	633	584	534
Preferred Stock	75	75	75
Total Common Equity	558	509	459
Common Stock	722	722	734
Retained Earnings	-199	-239	-294
Accumulated Other Comprehensive Income / (Loss)	35	25	19
Noncontrolling Interest	16	22	22

This table presents Global Medical REIT's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	1,407	1,369	1,321	1,303	1,264	1,241	1,243
Cash and Due from Banks	3.20	4.60	2.46	1.28	1.33	4.98	5.72
Restricted Cash	10	9.38	7.33	6.33	6.47	2.84	2.07
Interest Bearing Deposits at Other Banks	7.66	8.63	9.73	9.86	0.74	0.93	1.69
Trading Account Securities	37	27	36	38	29	28	15
Loans and Leases, Net of Allowance	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Premises and Equipment, Net	1,087	1,053	1,007	988	960	941	948
Deferred Acquisition Cost	29	30	26	27	28	28	28
Goodwill	5.90	5.90	5.90	5.90	5.90	5.90	5.90
Intangible Assets	148	148	140	139	139	136	138
Other Assets	78	81	86	87	93	93	98
Total Liabilities & Shareholders' Equity	1,407	1,369	1,321	1,303	1,264	1,241	1,243
Total Liabilities	742	741	679	669	666	663	678
Non-Interest Bearing Deposits	5.40	4.69	4.21	3.91	4.38	3.97	3.22
Short-Term Debt	635	635	568	561	592	599	614
Other Short-Term Payables	29	28	32	29	27	28	30
Long-Term Debt	58	57	57	57	26	15	14
Other Long-Term Liabilities	15	15	19	18	18	17	16
Total Equity & Noncontrolling Interests	665	628	641	634	597	578	565
Total Preferred & Common Equity	649	613	620	611	575	556	543
Preferred Stock	75	75	75	75	75	75	75
Total Common Equity	574	538	545	536	500	481	468
Common Stock	722	722	722	722	723	723	734
Retained Earnings	-185	-212	-214	-224	-252	-269	-281
Accumulated Other Comprehensive Income / (Loss)	37	27	36	38	29	28	15
Noncontrolling Interest	16	16	22	22	22	22	22

This table displays calculated financial ratios and metrics derived from Global Medical REIT's official financial filings.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-
Revenue Growth	16.43%	-1.69%	-0.06%
EBITDA Growth	9.83%	-6.40%	-8.62%
EBIT Growth	-23.33%	-46.82%	-40.32%
NOPAT Growth	-23.33%	-46.82%	-40.32%
Net Income Growth	9.02%	8.69%	-69.21%
EPS Growth	5.26%	15.00%	-95.65%
Operating Cash Flow Growth	10.98%	-10.58%	2.35%
Free Cash Flow Firm Growth	17.87%	218.02%	-85.58%
Invested Capital Growth	10.36%	-9.39%	-1.23%
Revenue Q/Q Growth	7.41%	-2.01%	1.48%
EBITDA Q/Q Growth	7.45%	-2.00%	-4.68%
EBIT Q/Q Growth	22.69%	-5.73%	-37.57%
NOPAT Q/Q Growth	-16.26%	-5.73%	-37.57%
Net Income Q/Q Growth	-15.40%	-5.63%	55.48%
EPS Q/Q Growth	-20.00%	-8.00%	150.00%
Operating Cash Flow Q/Q Growth	1.36%	-0.27%	3.54%
Free Cash Flow Firm Q/Q Growth	28.01%	17.22%	-70.23%
Invested Capital Q/Q Growth	-1.05%	-2.73%	0.72%
Profitability Metrics	-	-	-
EBITDA Margin	65.24%	62.12%	56.80%
EBIT Margin	11.82%	6.39%	3.82%
Profit (Net Income) Margin	17.85%	19.73%	6.08%
Tax Burden Percent	150.99%	308.63%	159.22%
Interest Burden Percent	100.00%	100.00%	100.00%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	1.03%	0.55%	0.35%
ROIC Less NNEP Spread (ROIC-NNEP)	2.09%	2.80%	0.74%
Return on Net Nonoperating Assets (RNNOA)	2.07%	2.91%	0.80%
Return on Equity (ROE)	3.11%	3.46%	1.15%
Cash Return on Invested Capital (CROIC)	-8.82%	10.40%	1.59%
Operating Return on Assets (OROA)	1.00%	0.53%	0.33%
Return on Assets (ROA)	1.51%	1.63%	0.53%
Return on Common Equity (ROCE)	2.67%	2.94%	0.96%
Return on Equity Simple (ROE_SIMPLE)	3.16%	3.72%	1.25%
Net Operating Profit after Tax (NOPAT)	13	7.04	4.20
NOPAT Margin	11.82%	6.39%	3.82%
Net Nonoperating Expense Percent (NNEP)	-1.06%	-2.25%	-0.40%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%
Operating Expenses to Revenue	88.18%	93.61%	96.18%
Earnings before Interest and Taxes (EBIT)	13	7.04	4.20
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	73	68	63
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	0.93	1.30	1.12
Price to Tangible Book Value (P/TBV)	1.28	1.82	1.64
Price to Revenue (P/Rev)	4.62	6.01	4.68
Price to Earnings (P/E)	38.84	44.77	635.91
Dividend Yield	10.64%	8.32%	10.88%
Earnings Yield	2.57%	2.23%	0.16%
Enterprise Value to Invested Capital (EV/IC)	0.95	1.12	1.04
Enterprise Value to Revenue (EV/Rev)	11.43	12.38	11.34
Enterprise Value to EBITDA (EV/EBITDA)	17.51	19.92	19.97
Enterprise Value to EBIT (EV/EBIT)	96.67	193.58	297.16
Enterprise Value to NOPAT (EV/NOPAT)	96.67	193.58	297.16
Enterprise Value to Operating Cash Flow (EV/OCF)	16.73	19.92	17.83
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	10.24	65.04
Leverage & Solvency	-	-	-
Debt to Equity	1.07	1.01	1.16
Long-Term Debt to Equity	0.09	0.04	0.03
Financial Leverage	0.99	1.04	1.08
Leverage Ratio	2.06	2.12	2.17
Compound Leverage Factor	2.06	2.12	2.17
Debt to Total Capital	51.68%	50.22%	53.75%
Short-Term Debt to Total Capital	47.38%	48.09%	52.55%
Long-Term Debt to Total Capital	4.29%	2.13%	1.20%
Preferred Equity to Total Capital	5.58%	6.16%	6.24%
Noncontrolling Interests to Total Capital	1.20%	1.83%	1.81%
Common Equity to Total Capital	41.54%	41.79%	38.20%
Debt to EBITDA	9.49	8.93	10.33
Net Debt to EBITDA	9.19	8.82	10.18
Long-Term Debt to EBITDA	0.79	0.38	0.23
Debt to NOPAT	52.41	86.80	153.73
Net Debt to NOPAT	50.73	85.75	151.43
Long-Term Debt to NOPAT	4.35	3.68	3.43
Noncontrolling Interest Sharing Ratio	14.05%	15.00%	16.69%
Liquidity Ratios	-	-	-
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-113	133	19
Operating Cash Flow to CapEx	0.00%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	-4.47	4.31	0.67
Operating Cash Flow to Interest Expense	3.03	2.22	2.44
Operating Cash Flow Less CapEx to Interest Expense	3.03	2.22	2.44
Efficiency Ratios	-	-	-
Asset Turnover	0.08	0.08	0.09
Fixed Asset Turnover	0.11	0.11	0.11
Capital & Investment Metrics	-	-	-
Invested Capital	1,343	1,217	1,202
Invested Capital Turnover	0.09	0.09	0.09
Increase / (Decrease) in Invested Capital	126	-126	-15
Enterprise Value (EV)	1,280	1,363	1,249
Market Capitalization	517	662	516
Book Value per Share	$8.52	$7.76	$6.87
Tangible Book Value per Share	$6.17	$5.55	$4.71
Total Capital	1,343	1,217	1,202
Total Debt	694	611	646
Total Long-Term Debt	58	26	14
Net Debt	672	604	636
Capital Expenditures (CapEx)	0.00	0.00	0.00
Net Nonoperating Expense (NNE)	-6.75	-15	-2.49
Net Nonoperating Obligations (NNO)	694	611	646
Total Depreciation and Amortization (D&A)	60	61	58
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	$0.20	$0.23	$0.01
Adjusted Weighted Average Basic Shares Outstanding	65.46M	65.55M	65.94M
Adjusted Diluted Earnings per Share	$0.20	$0.23	$0.01
Adjusted Weighted Average Diluted Shares Outstanding	65.46M	65.55M	65.94M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	65.53M	65.57M	66.87M
Normalized Net Operating Profit after Tax (NOPAT)	9.52	4.96	3.05
Normalized NOPAT Margin	8.49%	4.50%	2.77%
Pre Tax Income Margin	11.82%	6.39%	3.82%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.52	0.23	0.15
NOPAT to Interest Expense	0.52	0.23	0.15
EBIT Less CapEx to Interest Expense	0.52	0.23	0.15
NOPAT Less CapEx to Interest Expense	0.52	0.23	0.15
Payout Ratios	-	-	-
Dividend Payout Ratio	321.27%	298.37%	981.62%
Augmented Payout Ratio	321.27%	298.37%	981.62%

This table displays calculated financial ratios and metrics derived from Global Medical REIT's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	13.08%	37.66%	3.27%	-1.46%	-0.37%	-8.01%	0.96%	-2.27%	-4.62%	6.19%
EBITDA Growth	2.57%	39.75%	-3.91%	-8.70%	-5.15%	-7.83%	-1.97%	-5.38%	-8.93%	-18.72%
EBIT Growth	-38.97%	406.81%	-60.62%	-63.72%	-22.34%	-23.17%	37.09%	2.88%	-38.36%	-178.22%
NOPAT Growth	-38.97%	-58.19%	-60.62%	-63.72%	-22.34%	-23.17%	37.09%	2.88%	-38.36%	-154.76%
Net Income Growth	86.83%	-66.34%	-49.30%	269.77%	-51.81%	-70.17%	6.49%	-113.77%	-29.84%	433.39%
EPS Growth	100.00%	-83.33%	-75.00%	500.00%	-58.33%	-200.00%	0.00%	-127.78%	-40.00%	300.00%
Operating Cash Flow Growth	-1.58%	5.93%	-4.05%	-23.87%	-9.00%	-1.00%	-9.37%	5.87%	-2.18%	13.23%
Free Cash Flow Firm Growth	11.53%	17.31%	49.54%	127.14%	164.20%	202.67%	237.84%	73.77%	-45.40%	-88.85%
Invested Capital Growth	14.57%	10.36%	6.46%	-3.23%	-7.82%	-9.39%	-8.01%	-5.88%	-4.62%	-1.23%
Revenue Q/Q Growth	0.52%	-0.71%	-1.00%	-0.27%	1.63%	-8.33%	8.67%	-3.47%	-0.81%	2.06%
EBITDA Q/Q Growth	-1.16%	-3.52%	-2.04%	-2.26%	2.68%	-6.24%	4.18%	-5.65%	-1.17%	-16.32%
EBIT Q/Q Growth	-14.55%	-43.62%	-8.61%	-17.59%	82.89%	-44.22%	63.07%	-38.16%	9.57%	-170.79%
NOPAT Q/Q Growth	-14.55%	-43.62%	-8.61%	-17.59%	82.89%	-44.22%	63.07%	-38.16%	9.57%	-149.55%
Net Income Q/Q Growth	161.58%	-81.58%	17.65%	552.42%	-65.91%	-88.60%	319.96%	-184.36%	273.72%	-13.33%
EPS Q/Q Growth	300.00%	-91.67%	0.00%	1,700.00%	-72.22%	-120.00%	200.00%	-600.00%	160.00%	-33.33%
Operating Cash Flow Q/Q Growth	-22.01%	-0.03%	-13.86%	13.36%	-6.78%	8.75%	-21.14%	32.43%	-13.87%	25.89%
Free Cash Flow Firm Q/Q Growth	-5.20%	26.61%	36.88%	155.69%	148.87%	17.36%	-15.26%	-29.79%	-21.81%	-76.03%
Invested Capital Q/Q Growth	3.71%	-1.05%	-1.68%	-4.10%	-1.20%	-2.73%	-0.18%	-1.88%	0.12%	0.72%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
EBITDA Margin	64.91%	63.07%	62.40%	61.16%	61.79%	63.20%	60.59%	59.22%	59.00%	48.37%
EBIT Margin	11.52%	6.54%	6.04%	4.99%	8.98%	5.46%	8.20%	5.25%	5.80%	-4.02%
Profit (Net Income) Margin	35.26%	6.54%	7.77%	50.84%	17.06%	2.12%	8.20%	-7.16%	12.55%	10.65%
Tax Burden Percent	306.14%	100.00%	128.73%	1,019.19%	189.98%	38.83%	100.00%	-136.41%	216.26%	-264.77%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.95%	0.57%	0.53%	0.44%	0.77%	0.47%	0.71%	0.47%	0.51%	-0.26%
ROIC Less NNEP Spread (ROIC-NNEP)	2.03%	0.57%	0.61%	2.43%	1.12%	0.34%	0.71%	-0.08%	0.81%	0.33%
Return on Net Nonoperating Assets (RNNOA)	1.95%	0.57%	0.61%	2.42%	1.13%	0.35%	0.76%	-0.08%	0.84%	0.36%
Return on Equity (ROE)	2.90%	1.14%	1.14%	2.85%	1.91%	0.82%	1.48%	0.39%	1.35%	0.11%
Cash Return on Invested Capital (CROIC)	-12.33%	-8.82%	-5.42%	3.92%	8.71%	10.40%	8.95%	6.68%	5.28%	1.59%
Operating Return on Assets (OROA)	0.91%	0.55%	0.51%	0.42%	0.75%	0.45%	0.69%	0.45%	0.49%	-0.35%
Return on Assets (ROA)	2.78%	0.55%	0.66%	4.27%	1.42%	0.18%	0.69%	-0.61%	1.07%	0.93%
Return on Common Equity (ROCE)	2.50%	0.98%	0.98%	2.44%	1.63%	0.70%	1.25%	0.33%	1.14%	0.09%
Return on Equity Simple (ROE_SIMPLE)	3.64%	0.00%	2.92%	4.56%	3.77%	0.00%	3.80%	1.03%	0.79%	0.00%
Net Operating Profit after Tax (NOPAT)	3.28	1.85	1.69	1.39	2.54	1.42	2.31	1.43	1.57	-0.78
NOPAT Margin	11.52%	6.54%	6.04%	4.99%	8.98%	5.46%	8.20%	5.25%	5.80%	-2.82%
Net Nonoperating Expense Percent (NNEP)	-1.08%	0.00%	-0.08%	-1.99%	-0.35%	0.13%	0.00%	0.55%	-0.29%	-0.59%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	88.48%	93.46%	93.96%	95.01%	91.02%	94.54%	91.80%	94.75%	94.20%	104.02%
Earnings before Interest and Taxes (EBIT)	3.28	1.85	1.69	1.39	2.54	1.42	2.31	1.43	1.57	-1.11
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	18	18	17	17	18	16	17	16	16	13
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.83	0.93	0.99	1.01	1.01	1.30	1.12	1.24	1.39	1.12
Price to Tangible Book Value (P/TBV)	1.14	1.28	1.39	1.37	1.38	1.82	1.58	1.76	2.01	1.64
Price to Revenue (P/Rev)	4.57	4.62	4.73	4.87	4.80	6.01	5.08	5.42	5.99	4.68
Price to Earnings (P/E)	28.46	38.84	47.19	26.21	33.73	44.77	37.61	0.00	0.00	635.91
Dividend Yield	11.47%	10.64%	10.29%	10.04%	10.21%	8.32%	9.82%	9.25%	8.48%	10.88%
Earnings Yield	3.51%	2.57%	2.12%	3.82%	2.96%	2.23%	2.66%	0.00%	0.00%	0.16%
Enterprise Value to Invested Capital (EV/IC)	0.91	0.95	0.98	0.99	0.99	1.12	1.04	1.09	1.14	1.04
Enterprise Value to Revenue (EV/Rev)	11.88	11.43	11.47	11.11	11.00	12.38	11.47	11.82	12.60	11.34
Enterprise Value to EBITDA (EV/EBITDA)	18.21	17.51	17.89	17.67	17.72	19.92	18.61	19.32	20.83	19.97
Enterprise Value to EBIT (EV/EBIT)	114.82	96.67	121.65	152.47	165.58	193.58	165.24	168.31	202.97	297.16
Enterprise Value to NOPAT (EV/NOPAT)	78.37	96.67	121.65	152.47	165.58	193.58	165.24	168.31	202.97	297.16
Enterprise Value to Operating Cash Flow (EV/OCF)	16.41	16.73	17.07	17.80	18.02	19.92	18.92	19.08	20.20	17.83
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	24.77	10.89	10.24	11.17	15.79	21.18	65.04
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.04	1.07	1.10	0.97	0.97	1.01	1.03	1.06	1.11	1.16
Long-Term Debt to Equity	0.09	0.09	0.09	0.09	0.09	0.04	0.04	0.03	0.03	0.03
Financial Leverage	0.96	0.99	1.00	1.00	1.01	1.04	1.07	1.02	1.04	1.08
Leverage Ratio	2.05	2.06	2.07	2.08	2.09	2.12	2.15	2.10	2.12	2.17
Compound Leverage Factor	2.05	2.06	2.07	2.08	2.09	2.12	2.15	2.10	2.12	2.17
Debt to Total Capital	51.04%	51.68%	52.41%	49.36%	49.36%	50.22%	50.85%	51.48%	52.69%	53.75%
Short-Term Debt to Total Capital	46.77%	47.38%	48.07%	44.85%	44.82%	48.09%	48.74%	50.25%	51.48%	52.55%
Long-Term Debt to Total Capital	4.27%	4.29%	4.34%	4.51%	4.54%	2.13%	2.11%	1.23%	1.21%	1.20%
Preferred Equity to Total Capital	5.52%	5.58%	5.68%	5.92%	5.99%	6.16%	6.17%	6.29%	6.28%	6.24%
Noncontrolling Interests to Total Capital	1.17%	1.20%	1.19%	1.72%	1.77%	1.83%	1.82%	1.84%	1.85%	1.81%
Common Equity to Total Capital	42.27%	41.54%	40.72%	43.00%	42.88%	41.79%	41.16%	40.39%	39.18%	38.20%
Debt to EBITDA	10.18	9.49	9.56	8.83	8.85	8.93	9.07	9.14	9.59	10.33
Net Debt to EBITDA	9.87	9.19	9.25	8.56	8.60	8.82	8.95	9.01	9.44	10.18
Long-Term Debt to EBITDA	0.85	0.79	0.79	0.81	0.81	0.38	0.38	0.22	0.22	0.23
Debt to NOPAT	43.81	52.41	65.02	76.21	82.68	86.80	80.56	79.61	93.42	153.73
Net Debt to NOPAT	42.47	50.73	62.90	73.84	80.34	85.75	79.45	78.48	92.01	151.43
Long-Term Debt to NOPAT	3.66	4.35	5.39	6.96	7.61	3.68	3.35	1.90	2.15	3.43
Noncontrolling Interest Sharing Ratio	13.93%	14.05%	14.07%	14.48%	14.48%	15.00%	15.32%	15.88%	16.20%	16.69%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-169	-124	-78	44	109	128	108	76	59	14
Operating Cash Flow to CapEx	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	-24.31	-15.41	-9.48	5.16	15.16	18.26	15.69	10.85	8.20	1.88
Operating Cash Flow to Interest Expense	2.63	2.27	1.91	2.11	2.32	2.60	2.07	2.71	2.25	2.71
Operating Cash Flow Less CapEx to Interest Expense	2.63	2.27	1.91	2.11	2.32	2.60	2.07	2.71	2.25	2.71
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.08	0.08	0.09	0.08	0.08	0.08	0.08	0.09	0.09	0.09
Fixed Asset Turnover	0.10	0.11	0.11	0.11	0.11	0.11	0.11	0.11	0.11	0.11
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,357	1,343	1,321	1,267	1,251	1,217	1,215	1,192	1,193	1,202
Invested Capital Turnover	0.08	0.09	0.09	0.09	0.09	0.09	0.09	0.09	0.09	0.09
Increase / (Decrease) in Invested Capital	173	126	80	-42	-106	-126	-106	-74	-58	-15
Enterprise Value (EV)	1,239	1,280	1,295	1,251	1,237	1,363	1,267	1,297	1,366	1,249
Market Capitalization	477	517	535	548	540	662	561	596	650	516
Book Value per Share	$8.76	$8.52	$8.21	$8.31	$8.18	$7.76	$7.63	$7.34	$7.13	$6.87
Tangible Book Value per Share	$6.41	$6.17	$5.85	$6.09	$5.98	$5.55	$5.42	$5.17	$4.94	$4.71
Total Capital	1,357	1,343	1,321	1,267	1,251	1,217	1,215	1,192	1,193	1,202
Total Debt	693	694	692	625	618	611	618	614	629	646
Total Long-Term Debt	58	58	57	57	57	26	26	15	14	14
Net Debt	672	672	670	606	600	604	609	605	619	636
Capital Expenditures (CapEx)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Nonoperating Expense (NNE)	-6.75	0.00	-0.49	-13	-2.29	0.87	0.00	3.38	-1.82	-3.72
Net Nonoperating Obligations (NNO)	693	694	692	625	618	611	618	614	629	646
Total Depreciation and Amortization (D&A)	15	16	16	16	15	15	15	15	14	14
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.12	$0.01	$0.01	$0.18	$0.05	($0.01)	$0.01	($0.05)	$0.03	$0.02
Adjusted Weighted Average Basic Shares Outstanding	65.52M	65.46M	65.53M	65.54M	65.57M	65.55M	65.57M	65.59M	65.74M	65.94M
Adjusted Diluted Earnings per Share	$0.12	$0.01	$0.01	$0.18	$0.05	($0.01)	$0.01	($0.05)	$0.03	$0.02
Adjusted Weighted Average Diluted Shares Outstanding	65.52M	65.46M	65.53M	65.54M	65.57M	65.55M	65.57M	65.59M	65.74M	65.94M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	65.52M	65.53M	65.53M	65.56M	65.56M	65.57M	65.59M	65.59M	66.80M	66.87M
Normalized Net Operating Profit after Tax (NOPAT)	2.37	1.37	1.21	0.98	1.78	0.99	1.62	1.00	1.10	-0.67
Normalized NOPAT Margin	8.34%	4.86%	4.33%	3.50%	6.28%	3.82%	5.74%	3.68%	4.06%	-2.42%
Pre Tax Income Margin	11.52%	6.54%	6.04%	4.99%	8.98%	5.46%	8.20%	5.25%	5.80%	-4.02%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.47	0.23	0.20	0.16	0.35	0.20	0.34	0.20	0.22	-0.15
NOPAT to Interest Expense	0.47	0.23	0.20	0.16	0.35	0.20	0.34	0.20	0.22	-0.10
EBIT Less CapEx to Interest Expense	0.47	0.23	0.20	0.16	0.35	0.20	0.34	0.20	0.22	-0.15
NOPAT Less CapEx to Interest Expense	0.47	0.23	0.20	0.16	0.35	0.20	0.34	0.20	0.22	-0.10
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	268.92%	321.27%	360.20%	228.49%	280.81%	298.37%	297.57%	1,136.55%	1,519.49%	981.62%
Augmented Payout Ratio	268.92%	321.27%	360.20%	228.49%	280.81%	298.37%	297.57%	1,136.55%	1,519.49%	981.62%

Frequently Asked Questions About Global Medical REIT's Financials

When does Global Medical REIT's fiscal year end?

According to the most recent income statement we have on file, Global Medical REIT's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Global Medical REIT's net income changed over the last 2 years?

Global Medical REIT's net income appears to be on a downward trend, with a most recent value of $6.69 million in 2024, falling from $20.00 million in 2022. The previous period was $21.73 million in 2023. See Global Medical REIT's forecast for analyst expectations on what’s next for the company.

How has Global Medical REIT revenue changed over the last 2 years?

Over the last 2 years, Global Medical REIT's total revenue changed from $112.05 million in 2022 to $110.09 million in 2024, a change of -1.8%.

How much debt does Global Medical REIT have?

Global Medical REIT's total liabilities were at $700.57 million at the end of 2024, a 5.8% increase from 2023, and a 5.9% decrease since 2022.

How much cash does Global Medical REIT have?

In the past 2 years, Global Medical REIT's cash and equivalents has ranged from $1.28 million in 2023 to $6.82 million in 2024, and is currently $6.82 million as of their latest financial filing in 2024.

How has Global Medical REIT's book value per share changed over the last 2 years?

Over the last 2 years, Global Medical REIT's book value per share changed from 8.52 in 2022 to 6.87 in 2024, a change of -19.3%.

Related Companies

This page (NYSE:GMRE) was last updated on 5/3/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Global Medical REIT (GMRE) Financials

Frequently Asked Questions About Global Medical REIT's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Global Medical REIT (GMRE) Financials

Annual Income Statements for Global Medical REIT

Quarterly Income Statements for Global Medical REIT

Annual Cash Flow Statements for Global Medical REIT

Quarterly Cash Flow Statements for Global Medical REIT

Annual Balance Sheets for Global Medical REIT

Quarterly Balance Sheets for Global Medical REIT

Annual Metrics and Ratios for Global Medical REIT

Quarterly Metrics and Ratios for Global Medical REIT

Frequently Asked Questions About Global Medical REIT's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools